The new report from US Surgeon General Vivek H. Murthy, MD, MBA, highlights persistent disparities in tobacco use and ...

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with ...

Elinzanetant showed significant efficacy in reducing VMS frequency and severity, with rapid symptom improvement compared to ...

Panelists discuss the methodologies of the OASIS 1, 2, and 3 trials that investigated elinzanetant, highlighting key findings ...

Forecasts indicate a drastic increase in US obesity rates in the next 25 years, emphasizing the need for comprehensive public ...

FoundationOne Liquid CDx is now FDA-approved to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib ...

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

Mavacamten is approved for treating obstructive hypertrophic cardiomyopathy, with real-world data supporting its safety and efficacy. The REMS program is crucial for monitoring mavacamten's safety ...

Muvalaplin, an oral drug, significantly reduces Lp(a) levels by disrupting apo(a) and apoB bonding, achieving up to 85.5% reduction in a phase 2 study. Lp(a) is a genetically driven cardiovascular ...

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse ...

Of the 518 hospitals that had at least 10 eligible discharges, only 11 of them prescribed SGLT2 inhibitors to more than half ...